These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34592165)

  • 1. Statins for Graves' orbitopathy: a new tool for prevention and treatment?
    Bartalena L; Piantanida E; Tanda ML
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):726-727. PubMed ID: 34592165
    [No Abstract]   [Full Text] [Related]  

  • 2. Statin reduces orbitopathy risk in patients with Graves' disease by modulating apoptosis and autophagy activities.
    Bifulco M; Ciaglia E
    Endocrine; 2016 Sep; 53(3):649-50. PubMed ID: 26438397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins: A New Hope on the Horizon of Graves Orbitopathy?
    Marinò M; Lanzolla G; Marcocci C
    J Clin Endocrinol Metab; 2021 Jun; 106(7):e2819-e2821. PubMed ID: 33735381
    [No Abstract]   [Full Text] [Related]  

  • 4. Statins as potential addition to anti-Graves' ophthalmopathy armamentarium.
    Fallahzadeh MK; Namazi MR; Vakili H; Soveid M
    J Coll Physicians Surg Pak; 2009 Jun; 19(6):397. PubMed ID: 19486587
    [No Abstract]   [Full Text] [Related]  

  • 5. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
    Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy.
    Sabini E; Sisti E; Coco B; Leo M; Ionni I; Menconi F; Profilo MA; Mazzi B; Rocchi R; Latrofa F; Vitti P; Brunetto M; Marcocci C; Marinò M
    J Endocrinol Invest; 2016 Nov; 39(11):1323-1327. PubMed ID: 27465669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe.
    Rosetti S; Tanda ML; Veronesi G; Masiello E; Premoli P; Gallo D; Cusini C; Donati S; Sabatino J; Ippolito S; Piantanida E; Bartalena L
    J Endocrinol Invest; 2020 Mar; 43(3):381-383. PubMed ID: 31587179
    [No Abstract]   [Full Text] [Related]  

  • 8. Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.
    Covelli D; Vannucchi G; Campi I; Currò N; D'Ambrosio R; Maggioni M; Gianelli U; Beck-Peccoz P; Salvi M
    J Clin Endocrinol Metab; 2015 May; 100(5):1731-7. PubMed ID: 25751109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of graves' orbitopathy: early diagnosis of thyroid-associated orbitopathy in Graves' disease.
    Mourits MP
    Orbit; 2008; 27(6):399-400. PubMed ID: 19085291
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement.
    Bartalena L; Macchia PE; Marcocci C; Salvi M; Vermiglio F
    J Endocrinol Invest; 2015 Apr; 38(4):481-7. PubMed ID: 25722226
    [No Abstract]   [Full Text] [Related]  

  • 11. Do glucocorticoids affect outcome in Graves' disease following radioiodine therapy?
    Salvatore D; Fenzi G
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):194-5. PubMed ID: 16932282
    [No Abstract]   [Full Text] [Related]  

  • 12. Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease.
    Nilsson A; Tsoumani K; Planck T
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1325-1332. PubMed ID: 33560351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
    Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
    Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances in the pharmacological treatment of Graves' orbitopathy.
    Ruchała M; Sawicka-Gutaj N
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):981-9. PubMed ID: 26966785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study.
    Lai A; Sassi L; Compri E; Marino F; Sivelli P; Piantanida E; Tanda ML; Bartalena L
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1333-7. PubMed ID: 20061414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel treatment modalities for Graves' orbitopathy.
    Bartalena L; Lai A; Sassi L; Lombardi V; Dalle Mule I; Gandolfo M; Liparulo L; Azzolini C; Piantanida E; Tanda ML
    Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():210-6. PubMed ID: 20467365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
    Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioiodine therapy of Graves' hyperthyroidism in patients without pre-existing ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy?
    Dederichs B; Dietlein M; Jenniches-Kloth B; Schmidt M; Theissen P; Moka D; Schicha H
    Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):366-70. PubMed ID: 16915539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.